Form 4: Rhythm Pharmaceuticals CHRO Sells Shares to Cover Tax Obligations
Statement of Changes in Beneficial Ownership
Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, sold 1,520 shares of common stock for $85.93 per share to cover tax withholding related to the vesting of restricted stock units.
Summary
- Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc. (RYTM), reported transactions involving the company's common stock.
- On July 26, 2025, 3,125 restricted stock units (RSUs) vested and converted into 3,125 shares of common stock.
- Following this acquisition, Ms. Cramer's beneficial ownership of common stock was 22,334 shares.
- On July 29, 2025, Ms. Cramer sold 1,520 shares of common stock at a price of $85.93 per share.
- The sale was executed pursuant to a Rule 10b5-1 instruction adopted prior to February 27, 2023, solely to cover withholding taxes associated with the vesting of previously reported restricted stock units.
- After the sale, Ms. Cramer's direct beneficial ownership of common stock is 20,814 shares.
Sentiment
Score: 5
Explanation: The filing indicates a neutral sentiment as it details a routine, pre-planned transaction by an insider to cover tax obligations related to equity compensation, rather than a discretionary sale or purchase based on market sentiment.
Positives
- The vesting of 3,125 restricted stock units represents a realization of compensation for the Chief Human Resources Officer.
- The sale was conducted under a pre-arranged Rule 10b5-1 plan, indicating a non-discretionary transaction for tax purposes rather than a discretionary sale based on market outlook.
Negatives
- The disposition of 1,520 shares results in a net decrease in the Chief Human Resources Officer's direct beneficial ownership of common stock.
Future Outlook
NA
Industry Context
This filing represents a routine executive compensation transaction within the biotechnology and pharmaceutical industry, where restricted stock units are a common form of equity compensation.
Stakeholder Impact
- Shareholders: Minimal direct impact, as this is a routine, pre-planned transaction for tax purposes and does not signal a change in company fundamentals or management's long-term outlook.
- Employees: No direct impact beyond the reporting person.
Key Dates
| Date | Description |
|---|---|
| 07/26/2022 | First vesting date for restricted stock units. |
| 07/26/2023 | Second vesting date for restricted stock units. |
| 02/27/2023 | Date prior to which the Rule 10b5-1 instruction for the sale was adopted. |
| 07/26/2024 | Third vesting date for restricted stock units. |
| 07/26/2025 | Fourth and final vesting date for restricted stock units, and date of conversion of RSUs to common stock. |
| 07/29/2025 | Date of sale of common stock and filing date of the Form 4. |
Recommendation
holdThis Form 4 filing details a routine, pre-planned sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell.
Keywords
Rhythm Pharmaceuticals, RYTM, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Executive Compensation, Tax Withholding, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.